AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Editas Medicine, Inc.
Video analysis: EDIT
All videosNo video analysis for this stock yet. Request one from our team.
News: EDIT
Bank of New York Mellon Corp Invests $851,000 in Editas Medicine, Inc. $EDIT
Bank of New York Mellon Corp purchased a new position in shares of Editas Medicine, Inc. (NASDAQ: EDIT) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 262,625 shares of the company's stock, valued at approximately $851,000. Bank of New York Mellon Corp owned
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Editas Medicine NASDAQ: EDIT outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol.
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company's newly appointed Chief Medical Officer, Daniel Ory, M.D.
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
Editas Medicine NASDAQ: EDIT is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O'Neill said during a Wells Fargo discussion.
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development
BlackRock Inc. Takes Position in Editas Medicine, Inc. $EDIT
BlackRock Inc. acquired a new stake in Editas Medicine, Inc. (NASDAQ: EDIT) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,589,990 shares of the company's stock, valued at approximately $34,312,000. BlackRock Inc. owned approximately 10.82% of Editas Medicine at the
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare Conference Format: Fireside ChatDate: Tuesday, September 8Time: 4:30 p.m.
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
